In Vitro Drug-Drug Interaction Assays
Online Inquiry
In vitro drug interaction testing plays a crucial role in the development and evaluation of antibody drugs. It enables researchers and pharmaceutical companies to assess the potential interactions between antibody drugs and other drugs, providing valuable insights into their safety and efficacy. At Creative Proteomics, we offer comprehensive in vitro drug interaction testing services to support drug development programs and ensure the successful advancement of antibody drugs.
Overview of In Vitro Drug-Drug Interaction Assays
Drug-drug interactions alter the dose-effect relationship, may decrease efficacy or increase toxicity, and are important considerations when combining drugs for treatment in clinical applications. Predicting and evaluating drug-drug interactions of antibody drugs is an important part of benefit-risk assessment during drug development. In vitro drug-drug interaction studies are typically performed in a variety of in vitro models and combined with a series of in vitro assays, including CYP inhibition assays, transporter protein inhibition assays, and plasma protein binding assays. The data obtained from these assays can help identify potential drug-drug interactions and optimize therapeutic strategies for antibody drugs.
Our In Vitro Assays for Drug-Drug Interactions
Creative Proteomics' drug interaction assays cover three main areas:
The CYP450 enzyme family is the major enzyme involved in drug metabolism, accounting for approximately 80% of the total metabolizing enzymes. CYP450s are both inhibitable and inducible, and most drugs are inactivated by CYP enzymes, either directly or by facilitating excretion in vivo. Our experienced experts identify and assess potential drug-drug interactions by evaluating the interaction of antibody drugs with enzyme inhibitors or inducers in in vitro models.
- Transporter protein inhibition assays
Drug transporters play a crucial role in the development of drug-drug interactions by influencing the disposition of drugs in the body. Experiment specifically designed by Creative Proteomics to detect the effects of antibody drugs on transporter proteins include:
- Determining whether antibody drugs are substrates for the efflux transporters P-gp and BCRP.
- Determining whether the antibody drug is a substrate for the hepatic transporters OATP1B1 and OATP1B3.
- Determine whether the antibody drug is a substrate for the renal transporters OAT, OCT and MATE.
- Determine whether the antibody drug is an inhibitor of the transporters.
- Determine if the antibody drug is an inducer of the transporters.
With these tests, we can help our clients predict the likelihood of altered drug levels and potential interactions.
- Plasma protein binding assays
The high binding affinity of antibody drugs to plasma proteins also affects drug development in vivo, including processes such as drug distribution and clearance. Creative Proteomics' scientists can accurately assess the level of binding of antibody drugs to plasma proteins through plasma protein binding assay experiments, which help clients to identify potential drug-drug interactions and predict drug clearance.
Advantages of Our In Vitro Drug-Drug Interaction Assays
- Tailored experimental designs to meet the diverse needs of our clients.
- Comprehensive analytical assessment, including how different drugs interact with each other, taking into account factors such as pharmacokinetics, metabolism and binding affinity.
- Advanced in vitro assays combined with pharmacokinetic modeling and statistical analysis services to accurately assess drug-drug interactions.
Creative Proteomics offers comprehensive drug interaction research services that provide important insights into potential interactions between different drugs. Contact us to learn more about our service and we will be happy to serve you.
